Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Supemtek

Sanofi reception

Sanofi’s Priftin cleared for latent tuberculosis in the US

FDA approves Priftin with isoniazid for patients aged two years and older

- PMLiVE

The biosimilars are coming

Lilly on navigating the regulatory pathway for its insulin glargine

- PMLiVE

Sharing good diabetes practice in the NHS

Breaking down healthcare silos to demonstrate the benefits and adaptability of diabetes care initiatives

Sanofi reception

Sanofi plans 18 new product launches by 2020

Keen to reinstall faith of investors after firing CEO Viehbacher

- PMLiVE

EU approval for Gilead’s hep C combo Harvoni

Another boost for the company’s fast-growing Sovaldi franchise

- PMLiVE

PCSK9 inhibitor alirocumab works in statin-intolerance

Sanofi and Regeneron’s drug impresses at American Heart Association meeting

Sanofi reception

Sanofi persuades FDA to back its MS drug Lemtrada

But only for a limited patient population, with boxed warnings and a risk plan

European Commission forms €2.5bn big data partnership

Says mastering data will lead to better health outcomes

- PMLiVE

Sanofi board votes out CEO Viehbacher

Unanimous decision ends weeks of speculation

EU flag

EC: medicines to remain part of health directorate

Juncker U-turns on decision to move pharma oversight to enterprise and industry

- PMLiVE

Amgen files lawsuit to block PCSK9 rivals

Firm suing Sanofi and Regeneron for patent infringement

Sanofi reception

Sanofi to work with Immune Design on herpes vaccine

Both companies have separate vaccines in development but will pool resources

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links